When high grade serous ovarian cancer patient-derived primary cells (p53-R248Q) were treated with ReACp53, cytosolic p53 punctate bodies (indicative of protein aggregation) were reduced and nuclear p53 increased, indicative of dis-aggregation and successful refolding (Soragni et al., 2016). The gene discussed is TP53; the disease is ovarian serous adenocarcinoma.